PMID- 24307221
OWN - NLM
STAT- MEDLINE
DCOM- 20150408
LR  - 20220330
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 31
IP  - 1
DP  - 2014 Jan
TI  - Comparative short-term effect of once-daily molsidomine on chronic angina in 
      general practitioners' versus cardiologists' coronary patient populations.
PG  - 91-106
LID - 10.1007/s12325-013-0079-3 [doi]
AB  - INTRODUCTION: The direct nitric oxide donor molsidomine is commonly used to 
      relieve symptoms in chronic angina thanks to its vasodilatory properties that 
      induce both a reduction in myocardial oxygen demand and an increase in coronary 
      blood flow. The objective of this study was to compare the short-term effect of 
      molsidomine 16 mg once daily (Coruno((R)), Therabel Pharmaceuticals Ltd, Dublin, 
      Ireland) in patients with stable angina previously on molsidomine 8 mg twice 
      daily, in care of general practitioners (GPs) versus cardiologists. METHODS: A 
      total of 53 and 80 patients treated by GPs and cardiologists, respectively, took 
      part in this multicenter, open-label clinical trial. Frequency of anginal 
      attacks, short-acting nitroderivative tablets consumption, and subjective 
      clinical status were evaluated, as was tolerability to molsidomine through the 
      reporting of adverse events (AEs), the recording of vital parameters-resting 
      blood pressure, heart rate, and electrocardiogram-and routine blood analyses. 
      RESULTS: Although demographic and clinical characteristics were significantly 
      different in GPs' compared with cardiologists' patients, the effect of either the 
      8 mg or the 16 mg molsidomine formulation on anginal crises and nitroderivatives 
      consumption was similar in both patient cohorts, with a trend for the 16 mg 
      formulation to be more efficient on symptoms in elderly patients. Subjective 
      assessment of the beneficial effect of molsidomine 16 versus 8 mg was comparable 
      in GPs' and cardiologists' patients independently of age, "no change" being the 
      most often reported item. Self-evaluation of functional capacity in elderly 
      showed on the whole no difference between the two patient cohorts, only magnitude 
      of pace and total score on molsidomine 16 mg being higher in cardiologists' 
      compared with GPs' patients, and total score in cardiologists' patients higher on 
      molsidomine 16 mg compared with 8 mg. Incidences of AEs and drug-related AEs, as 
      well as proportions of patients reporting such AEs, were similar between GPs' and 
      cardiologists' patient cohorts as between molsidomine 8 and 16 mg formulations. 
      Molsidomine 16 mg once daily had no clinically significant effect on blood 
      pressure, heart rate, electrocardiogram or blood parameters, and compliance with 
      treatment was excellent in whatever patient cohort. CONCLUSION: Despite 
      significant demographic and clinical differences between patients in care of GPs 
      and cardiologists, molsidomine was equally efficient in these two patient 
      cohorts, with a trend towards less anginal attacks in the elderly when treated 
      with the 16 mg compared with the 8 mg formulation. Compliance and tolerability to 
      the drug were excellent in both patient cohorts.
FAU - Messin, Roger
AU  - Messin R
AD  - Therabel Pharma S.A., Rue Egide Van Ophem 108, 1180, Brussels, Belgium, 
      roger.messin@therabel.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20131204
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Vasodilator Agents)
RN  - D46583G77X (Molsidomine)
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina, Stable/*drug therapy
MH  - Cardiology
MH  - Drug Administration Schedule
MH  - Female
MH  - General Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molsidomine/*administration & dosage
MH  - Treatment Outcome
MH  - Vasodilator Agents/*administration & dosage
EDAT- 2013/12/07 06:00
MHDA- 2015/04/09 06:00
CRDT- 2013/12/06 06:00
PHST- 2013/10/11 00:00 [received]
PHST- 2013/12/06 06:00 [entrez]
PHST- 2013/12/07 06:00 [pubmed]
PHST- 2015/04/09 06:00 [medline]
AID - 10.1007/s12325-013-0079-3 [doi]
PST - ppublish
SO  - Adv Ther. 2014 Jan;31(1):91-106. doi: 10.1007/s12325-013-0079-3. Epub 2013 Dec 4.